ROR2 antibody compositions and related methods
The disclosure provides antibodies, antibody fragments or antigen-binding fragments, as well as related antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR2, Also provided in the disclosure are methods of using such antibodies in various diagnostic and therapeutic applications.
1. An antibody, an antibody-based binding protein or an antibody fragment that specifically binds to the extracellular domain of human receptor tyrosine kinase-like orphan receptor 2 (ROR2), comprising heavy chain CDR1-3 sequences and light chain CDR1-3 sequences that are respectively identical to SEQ ID NOs:25-27 and SEQ ID NOs:61-63.
2. The antibody, antibody-based binding protein or antibody fragment of claim 1 , comprising a heavy chain variable region sequence and a light chain variable region sequence that are at least 95% identical to SEQ ID NO:1 and SEQ ID NO:13, respectively.
3. The antibody, antibody-based binding protein or antibody fragment of claim 1 , comprising a heavy chain variable region sequence and a light chain variable region sequence respectively shown in SEQ ID NO:1 and SEQ ID NO:13.
4. The antibody, antibody-based binding protein or antibody fragment of claim 1 , wherein the antibody or antibody fragment is chimeric or humanized.
5. The antibody, antibody-based binding protein or antibody fragment of claim 1 , wherein the antibody or antibody fragment is IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, synthetic IgG, IgM, F(ab)2, Fv, scFv, IgGACH2, F(ab′)2, scFv2CH3, Fab, VL, VH, scFv4, scFv3, scFv2, dsFv, Fv, scFv-Fc, (scFv)2, a non-depleting IgG, a diabody, or a bivalent antibody.
6. The antibody, antibody-based binding protein or antibody fragment of claim 1 , which is conjugated to a synthetic molecule.
7. The antibody, antibody-based binding protein or antibody fragment of claim 6 , wherein the synthetic molecule is a cytotoxic agent, a label, a therapeutic radioisotope, or a liposome.
8. A pharmaceutical composition comprising (1) a therapeutically effective amount of an antibody, antibody-based binding protein or antibody fragment of claim 1 , and (2) a pharmaceutically acceptable carrier.
9. A kit comprising the antibody or antigen-binding fragment of claim 1 .
10. An antibody drug conjugate (ADC), comprising an antibody, an antibody-based binding protein or an antibody fragment that specifically binds to the extracellular domain of human receptor tyrosine kinase-like orphan receptor 2 (ROR2), comprising heavy chain CDR1-3 sequences and light chain CDR1-3 sequences that are respectively identical to SEQ ID NOs:25-27 and SEQ ID NOs:61-63.
11. The antibody drug conjugate of claim 10 , wherein the cytotoxic agent is a small molecular weight toxin, a peptide toxin, or a protein toxin.
12. The antibody drug conjugate of claim 10 , wherein the antibody or antibody fragment comprises a heavy chain variable region sequence and a light chain variable region sequence respectively shown in SEQ ID NO:1 and SEQ ID NO:13.
13. A pharmaceutical composition comprising (1) a therapeutically effective amount of an antibody drug conjugate (ADC) of claim 10 , and (2) a pharmaceutically acceptable carrier.